Bora Pharmaceuticals Co. Ltd., a pharmaceutical manufacturer, has completed its acquisition of Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland—adding drug product fill/finish to its biologics drug substance capabilities.
 
The newly acquired 87,000-sq. ft. facility provides drug product manufacturing services for sterile injectables. It offers clinical and commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services.
 
“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” said Bobby Sheng, Chairman and CEO of Bora Group. “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”
 
Bora completed the acquisition of Upsher-Smith Laboratories, the Minnesota-based generics manufacturer and marketer, earlier this year, adding oral dose capabilities at two facilities in Plymouth and Maple Grove, Minnesota. The company’s global CDMO network now includes ten high quality manufacturing facilities serving customers across dose forms and delivery technologies.